To be short, treating BRAFMT thyroid cancer with simple PLX4032 will induce a feedback activation of MAPK/ERK as well as PI3K/AKT pathways, leading to the drug resistance and cell survival (Fig. 7b). Here, AKT1 is linked to thyroid gland carcinoma.